Patient Five and Six Demonstrate No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis Company Successfully Completes 180 days Follow Up of the Phase Ib Study and Plans Regulatory Filings to Commence a Phase II Clinical Study that May Lead to Commercialization of the TLD-1433 Anti-Cancer Technology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) Toronto, Ontario – August 13, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has provided an update on patient six, enrolled and treated in the recently completed Phase Ib NMIBC clinical study (“Study”). The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, with a secondary endpoint of pharmacokinetics (movement and exit of … Read More

Toronto, Ontario – July 26, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy cancer released its 2Q2018 financial statements.Total revenue for the six-month period ended June 30, 2018 decreased to $910,690 from $1,016,734 for the same period in 2017, a 10% decrease. In Canada, revenue decreased 22% to $602,277 from $769,840. In the US, revenue decreased 13% to $183,460 from $211,453 and international revenue increased 252% to $124,953 from $35,441. The increase in international revenue in 2018 and the corresponding decrease in Canadian and US revenue is attributable to the Company hiring an International Sales Manager and restructuring the Canadian and US sales and marketing departments. Cost of sales for the six-month period ended June 30, 2018 … Read More

Patient Five Demonstrates No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis Toronto, Ontario – July 16, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has provided an update on patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”). The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy. The exploratory outcome endpoint is defined as Recurrence-Free Survival (“RFS”), which is the interval from the day of the treatment to documented recurrence or death from any cause, … Read More

Toronto, Ontario – June 29, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations used to safely and effectively destroy cancer is pleased to announce the release of three videos presented at the completion of the Company’s Annual and Special Meeting, held at the Company’s corporate office on June 22, 2018. The videos are as follows: Girish Kulkarni MD, Surgeon-scientist affiliated with the Department of Surgery, Faculty of Medicine at the University of Toronto discusses the successful completion of the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study https://youtu.be/a_tacy_kND8 Michael Jewett MD, Professor of Surgery (Urology) at the University of Toronto discusses the proposed design of the Phase II NMIBC clinical study https://youtu.be/ytXPx0Ltb_Q Manjunatha Ankathatti Munegowda, Ph.D., DVM, Research Scientist, Theralase discusses the potential opportunities … Read More

Toronto, Ontario – June 22, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations used to safely and effectively destroy various cancers is pleased to announce that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for the U.S. Patent Application No. 15/291,025: “Metal-Glycoprotein Complexes And Photodynamic Therapy Of Immune Privileged Sites With Same” that encompasses the Company’s Rutherrin® Based Photo Dynamic Therapy (“PDT”) for the treatment of cancers localised in immune privileged sites, such as: the eyes, brain and testis.   Inflammation, particularly at an immune-privileged site, induced by surgery, radiation or another anti-cancer modality may act as a “double edged sword”. On the positive side, an increase in inflammation may help trigger the activation of the body’s … Read More

Toronto, Ontario – June 11, 2018, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, intended to safely and effectively destroy cancer, has announced significant benefits of its Rutherrin® (TLD-1433 + transferrin) formulation in comparison to a clinically approved PDC Amino Levulinic Acid (“ALA”), in the destruction of Rat Glioma (“RG2”) brain tumours, representative of GlioBlastoma Multiforme (“GBM”), a deadly form of human brain cancer. As previously disclosed, Theralase demonstrated that rats subjected to RG2 cancer cells, developed brain tumours representative of GBM. After intravenous (“IV”) injection of Rutherrin® and subsequent laser light activation, these animals survived significantly longer that animals who did not receive treatment and/or were treated with ALA-PDT. Further research conducted by Theralase researchers has demonstrated that Rutherrin® is able to provide a significant (up to 400 %) improvement in survival in animals treated with … Read More

Theralase Medical and Scientific Advisory Board concluded that the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) has met its objectives and unanimously voted for the early termination of the Study based on successfully achieving its primary and secondary endpoints after six patients. Toronto, Ontario – May 30, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy cancer has successfully completed the Study. On May 19, 2018, Theralase’s Medical and Scientific Advisory Board (“MSAB”) was convened to examine the clinical results obtained on the first six patients enrolled and treated in the Study utilizing TLD-1433-based Photo Dynamic Therapy (“PDT”); specifically: the primary endpoint of safety and tolerability, the secondary endpoint of pharmacokinetics (movement and exit of … Read More

Patient Five Shows No Clinical Evidence or Presence of NMIBC at 90 Day Cystoscopy Analysis Patient Six Shows No Clinical Evidence or Presence of NMIBC to Date Toronto, Ontario – April 16, 2018  Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, provides an update on the Phase Ib NMBIC clinical study (“Study”) currently in progress. The Study is being used to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy. The exploratory outcome endpoint is determined by Recurrence-Free Survival, defined as the interval from Day 0 to documented recurrence or death from any cause, whichever occurs first. … Read More

Toronto, Ontario – April 30, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, announced today that for the year ended December 31, 2017, total revenue increased to $2,342,508 from $1,918,893 in 2016, a 22% increase. In Canada, revenue increased 36% to $1,942,010 from $1,423,181. In the US, revenue decreased 37% to $261,833 from $416,812 while, international revenue increased 76% to $138,665 from $78,900. The increase in Canadian and international revenue in 2017 and the corresponding decrease in US revenue is attributable to the Company’s sales and marketing team focusing on the Canadian and international markets. Cost of sales for the year ended December 31, 2017 was $945,010 (40% of revenue) resulting in a gross margin of … Read More

Patient Six Demonstrates No Clinical Evidence of NMIBC at 90 Day Cystoscopy Analysis Toronto, Ontario – May 17, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers provides an update on the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) currently in progress. The Study is being used to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy. The exploratory outcome endpoint is Recurrence-Free Survival (“RFS”), defined as the interval from Day 0 to documented recurrence or death from any cause, whichever occurs first. Recurrence is defined as any new tumour growth (i.e: any biopsy-confirmed … Read More